Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267137 · ClinicalTrials.gov registry record · NA
Study for Atrial Fibrillation Reduction (SAFARI)
A NA study of Atrial Fibrillation, Bradycardia, sponsored by Medtronic Cardiac Ablation Solutions.
- Completed
- Registry status
- NA
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT00267137: Completed NA study of Atrial Fibrillation, Bradycardia, sponsored by Medtronic Cardiac Ablation Solutions.
NCT00267137 is a NA study of Atrial Fibrillation, Bradycardia that has completed, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 540 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267137, a NA study of Atrial Fibrillation, Bradycardia, has completed, sponsored by Medtronic Cardiac Ablation Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
Atrial fibrillation (AF), which is the name for rapid beats in the upper chambers of the heart, is the world's most common kind of irregular heart beat. People with AF experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness. Although AF can occur in otherwise healthy people for no apparent reason, it is sometimes associated with high blood pressure, heart disease or lung problems. The purpose of the SAFARI trial is to study the effectiveness of pacing algorithms in the upper chamber of the heart for patients who have both AF and bradycardia (slow heart beat).
Conditions Studied
Interventions
- DEVICE Pacing Algorithms
Study Locations (20)
Florida
- - Clearwater
- - Daytona Beach
- - Ormond Beach
- - Tampa
California
- - Bakersfield
- - Berkeley
- - Los Angeles
Illinois
- - Chicago
- - Lombard
- - Springfield
Arkansas
- - Fayetteville
- - Fort Smith
Arizona
- - Yuma
Colorado
- - Aurora
Connecticut
- - Stamford
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2002-09 |
| Est. Completion | 2006-07-21 |
| Phase | NA |
What the finished NCT00267137 record still lists
NCT00267137 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Atrial Fibrillation, Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Pacing Algorithms is the first listed.
NCT00267137 names 20 study sites across 12 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00267137 about?
NCT00267137 is a clinical study titled "Study for Atrial Fibrillation Reduction (SAFARI)". Atrial fibrillation (AF), which is the name for rapid beats in the upper chambers of the heart, is the world's most common kind of irregular heart beat. People with AF experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue ...
What is the current status of trial NCT00267137?
This trial is currently completed. It is a NA study. The enrollment target is 540 participants. The study started on 2002-09. Estimated completion is 2006-07-21.
What conditions does trial NCT00267137 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Bradycardia.
What interventions are being tested in trial NCT00267137?
The interventions under investigation include: Pacing Algorithms (DEVICE).
Who is sponsoring clinical trial NCT00267137?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267137 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00267137's enrollment target sits among peer trials
540 187th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia